SGYP - Synergy Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.0300
-0.0325 (-52.00%)
As of 4:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0625
Open0.0644
Bid0.0000 x 900
Ask0.0000 x 34100
Day's Range0.0300 - 0.0644
52 Week Range0.0300 - 2.1000
Volume51,182,897
Avg. Volume15,260,566
Market Cap7.441M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire22 hours ago

    INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceuticals, Inc. (SGYP) and Lead Deadline: April 12, 2019

    This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On September 5, 2017, Synergy entered into a $300 million senior secured loan from CRG Partners III L.P. (“CRG” and the “CRG Loan”), which in its initial incarnation provided an immediate cash infusion of $100 million with a second $100 million tranche of financing less than six months later, on or before February 28, 2018, and a third tranche of up to $100 million in the following thirteen months.

  • ACCESSWIREyesterday

    INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceutical, Inc. (SGYP) and Lead Deadline: April 12, 2019

    NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Synergy Pharmaceutical, Inc. (''Synergy'' or the ''Company'') (SGYP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Synergy securities during the period between September 5, 2017, and October 25, 2018, (the ''Class Period''). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On September 5, 2017, Synergy entered into a $300 million senior secured loan from CRG Partners III L.P. (''CRG'' and the ''CRG Loan''), which in its initial incarnation provided an immediate cash infusion of $100 million with a second $100 million tranche of financing less than six months later, on or before February 28, 2018, and a third tranche of up to $100 million in the following thirteen months.

  • ACCESSWIRE3 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. (''Synergy'' or the ''Company'') (SGYP) against certain of the Company's current and former officers and directors. The class action, filed in United States District Court, Eastern District of New York, and indexed under 19-cv-01352, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired publicly traded securities of Synergy between September 5, 2017, and October 25, 2018, both dates inclusive (the ''Class Period''), brought against Troy Hamilton (''Hamilton''), Gary G. Gemignani (''Gemignani''), and Gary S. Jacob (''Jacob'') (collectively, ''Defendants'') for the dissemination of materially false and misleading statements and omissions and concealment of material adverse facts in violation of the Securities Exchange Act of 1934 (the ''Exchange Act'').

  • ACCESSWIRE3 days ago

    SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceutical, Inc. (SGYP) and Lead Deadline: April 12, 2019

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Synergy Pharmaceutical, Inc. (''Synergy'' or the ''Company'') (SGYP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Synergy securities during the period between September 5, 2017, and October 25, 2018, (the ''Class Period''). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On September 5, 2017, Synergy entered into a $300 million senior secured loan from CRG Partners III L.P. (''CRG'' and the ''CRG Loan''), which in its initial incarnation provided an immediate cash infusion of $100 million with a second $100 million tranche of financing less than six months later, on or before February 28, 2018, and a third tranche of up to $100 million in the following thirteen months.

  • ACCESSWIRE7 days ago

    SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Synergy Pharmaceutical, Inc. (SGYP) and Lead Deadline: April 12, 2019

    NEW YORK, NY / ACCESSWIRE / March 15, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Synergy Pharmaceutical, Inc. ("Synergy" or the "Company") (SGYP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Synergy securities during the period between September 5, 2017, and October 25, 2018, (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On September 5, 2017, Synergy entered into a $300 million senior secured loan from CRG Partners III L.P. ("CRG" and the "CRG Loan"), which in its initial incarnation provided an immediate cash infusion of $100 million with a second $100 million tranche of financing less than six months later, on or before February 28, 2018, and a third tranche of up to $100 million in the following thirteen months.

  • GlobeNewswire8 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

    NEW YORK, March 14, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. (“Synergy” or the.

  • The Wall Street Journal10 days ago

    [$$] Synergy Pharma Bankruptcy Plan Cleared for Creditor Poll

    Inc. won court permission to move forward with the second phase of its bankruptcy, winding down what remains of the company following the sale of its assets. In the U.S. Bankruptcy Court in New York Tuesday, Judge James Garrity Jr. approved a blueprint of the company’s wind-down plan, which will soon be sent out to creditors for a vote. Court papers show creditors have until April 11 to cast their ballots. Synergy hopes to win final approval of the plan, which splits the remaining sale proceeds between junior and senior lenders, at another hearing scheduled for April 23. Under the plan, unsecured creditors are guaranteed to take home at least $13 million as well as a chance to share in the proceeds resulting from future lawsuits.

  • GlobeNewswire11 days ago

    SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Class Action Against Synergy Pharmaceutical, Inc. (SGYP) and Lead Plaintiff Deadline: April 12, 2019

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Synergy Pharmaceutical, Inc. (“Synergy” or the “Company”) (SGYP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Synergy securities during the period between September 5, 2017, and October 25, 2018, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/sgyp. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On September 5, 2017, Synergy entered into a $300 million senior secured loan from CRG Partners III L.P. (“CRG” and the “CRG Loan”), which in its initial incarnation provided an immediate cash infusion of $100 million with a second $100 million tranche of financing less than six months later, on or before February 28, 2018, and a third tranche of up to $100 million in the following thirteen months.

  • GlobeNewswire15 days ago

    Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in Synergy Pharmaceuticals, Inc. – SGYP

    NEW YORK, March 07, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. (“Synergy” or the.

  • PR Newswire16 days ago

    Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.

    LAVAL, Quebec, March 6, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company has completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with Synergy and following approval by the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") on March 1, 2019. "We are excited to welcome new team members from Synergy to join our Salix Pharmaceuticals business, a leader in gastroenterology.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

    Synergy Pharmaceuticals Inc NASDAQ/NGS:SGYPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for SGYP with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding SGYP totaled $4 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Chester County to lose 137 pharma jobs
    American City Business Journals18 days ago

    Chester County to lose 137 pharma jobs

    A New York biopharmaceutical company is closing its Chesterbrook office after reaching a deal to sell most of its assets.

  • PR Newswire21 days ago

    Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health

    NEW YORK, March 1, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement with Bausch Health Companies Inc. has been approved by the Bankruptcy Court. The sale of Synergy's assets, including all rights to TRULANCE® (plecanatide), dolcanatide and related intellectual property, is now expected to close on or about March 5, 2019. Synergy on December 12, 2018, initiated voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York to facilitate a sale and address its debt obligations.

  • GlobeNewswire22 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synergy Pharmaceuticals Inc. - SGYP

    Pomerantz LLP is investigating claims on behalf of investors of Synergy Pharmaceuticals Inc. (“Synergy” or the “Company”) (NASDAQ:  SGYP).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. Following this news, Synergy’s stock price fell $0.97 per share, or 69.3%, to close at $0.43 per share on October 26, 2018.

  • Benzinga23 days ago

    The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 26) AstraZeneca plc (NYSE: AZN )(announced positive results ...

  • PR Newswire24 days ago

    Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.

    LAVAL, Quebec, Feb. 26, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the Company (as described below). "As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses.

  • PR Newswire24 days ago

    Synergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business Assets

    NEW YORK, Feb. 26, 2019 /PRNewswire/ -- Synergy Pharmaceuticals Inc. (SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced agreement with Bausch Health Companies Inc. has been designated as the highest and best offer for Synergy's assets, including all rights to TRULANCE® (plecanatide), dolcanatide and related intellectual property. The auction scheduled for February 26, 2019, did not proceed, as no party submitted a higher and better bid in accordance with the bidding procedures established by the U.S. Bankruptcy Court for the Southern District of New York. Synergy currently expects the agreement with Bausch Health will be approved by the Bankruptcy Court on March 1, 2019, and that the proposed sale will be completed shortly thereafter.

  • The Wall Street Journal25 days ago

    [$$] Puerto Rico's Debt Saga May Land Back in Washington's Lap

    Puerto Rico’s financial restructuring is ricocheting in a new direction after a court ruling threatened to leave the U.S. territory without functioning fiscal supervisors for the first time since it defaulted ...

  • The Wall Street Journal28 days ago

    [$$] Synergy Pharmaceuticals Wins Approval for Bankruptcy Loan

    Inc. won court permission to draw down the remainder of a $155 million bankruptcy financing package, overcoming roadblocks imposed by a newly empowered committee of shareholders. Approval of the settlement and financing, which follow hearings on the matters Thursday and Friday at the U.S. Bankruptcy Court in New York, will keep the company firmly on track to sell its assets an auction later this month and then move toward final approval of a debt-repayment plan in April. A group of shareholders have been vocal opponents of Synergy’s bankruptcy plans since the outset of the case late last year.

  • PR Newswirelast month

    Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.

    NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Synergy Pharmaceuticals Inc. ("Synergy" or the "Company") ...

  • Bausch Health Companies Inc (BHC) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Bausch Health Companies Inc (BHC) Q4 2018 Earnings Conference Call Transcript

    BHC earnings call for the period ending December 31, 2018.